摘要:
The invention relates to a tumour-associated peptide containing an amino acid sequence, which is selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 79 of the enclosed sequence protocol. Said peptide has the capacity to bond to a molecule of the human major histocompatibility complex (MHC) class I. The invention also relates to the use of the peptides for producing a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
摘要:
The invention relates to a peptide for triggering an immune response to tumor cells. Said peptide has an optionally modified fragment of the protein that is encoded by the gene MUC-1. Said protein triggers an HLA-A2-restricted immune response.
摘要:
The invention relates to a method for identifying immunoreactive peptides. According to said method, a sample consisting of tumorous and corresponding healthy tissue is first prepared, the tumour-specific expression profile is subsequently determined and antigenic peptides are isolated from the tumorous tissue and analysed. The respective data that has been obtained is then matched and peptides are identified on the basis of said matched data.
摘要:
The invention relates to a method for identifying immunoreactive peptides. According to said method, a sample consisting of tumorous and corresponding healthy tissue is first prepared, the tumour-specific expression profile is subsequently determined and antigenic peptides are isolated from the tumorous tissue and analysed. The respective data that has been obtained is then matched and peptides are identified on the basis of said matched data.
摘要:
The invention relates to a tumour-associated peptide having an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 101 from the associated sequence protocol, said peptide being able to bind to a molecule of the human major histocompatibility complex (MHC) class I. The invention also relates to the use of said peptides and the nucleic acids coding therefor, for producing a medicament and for the treatment of tumour diseases and/or adenomatous diseases. The invention further relates to a pharmaceutical composition comprising at least one of said peptides.
摘要翻译:本发明涉及具有选自相关序列方案的SEQ ID No.1至SEQ ID No.101的氨基酸序列的肿瘤相关肽,所述肽能够结合人类主要分子 组织相容性复合体(MHC)I类。本发明还涉及所述肽及其编码核酸在生产药物和治疗肿瘤疾病和/或腺瘤疾病中的用途。 本发明进一步涉及包含至少一种所述肽的药物组合物。
摘要:
The invention relates to a tumour-associated peptide containing an amino acid sequence, which is selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 79 of the enclosed sequence protocol. Said peptide has the capacity to bond to a molecule of the human major histocompatibility complex (MHC) class I. The invention also relates to the use of the peptides for producing a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.